Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · IEX Real-Time Price · USD
4.500
+0.580 (14.80%)
At close: Apr 18, 2024, 4:00 PM
4.470
-0.030 (-0.67%)
After-hours: Apr 18, 2024, 7:57 PM EDT

Aquestive Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Cash & Equivalents
23.8727.2728.0231.8149.3360.617.389.21
Cash & Cash Equivalents
23.8727.2728.0231.8149.3360.617.389.21
Cash Growth
-12.47%-2.68%-11.89%-35.52%-18.60%248.69%88.72%-
Receivables
8.474.712.126.9613.136.486.1810.82
Inventory
6.775.784.042.462.865.444.012.89
Other Current Assets
1.852.133.083.431.680.590.42
Total Current Assets
40.9739.8947.2644.6368.3174.228.1623.33
Property, Plant & Equipment
9.749.37.7810.329.7312.2113.4615.12
Goodwill and Intangibles
1.281.440.050.10.150.440.250.31
Other Long-Term Assets
5.446.456.97.840.2901.240.63
Total Long-Term Assets
16.4517.1814.7318.2610.1712.6514.9516.06
Total Assets
57.4257.0761.9962.8878.4886.8543.1239.39
Accounts Payable
8.939.958.317.0912.2720.449.66.64
Deferred Revenue
33.932.937.894.335.150.721.350.8
Current Debt
1.3320.14.154.7504.600
Other Current Liabilities
-25.85-23.451.614.941.137.24.43.37
Total Current Liabilities
18.3139.5321.9621.118.5632.9515.3510.81
Long-Term Debt
111.24102.65112.5684.760.3442.645.5138.65
Other Long-Term Liabilities
34.3633.459.615.585.711.228.7547.13
Total Long-Term Liabilities
145.6136.1122.1690.2866.0543.8254.2685.78
Total Liabilities
163.91175.62144.13111.3884.676.7769.6196.59
Total Debt
112.57122.75116.7189.4560.3447.245.5138.65
Debt Growth
-8.29%5.18%30.47%48.25%27.83%3.73%17.74%-
Retained Earnings
-319.08-311.21-256.8-186.26-130.47-61.38-120.09-108.67
Shareholders' Equity
-106.49-118.55-82.13-48.5-6.1210.08-68.6-57.2
Net Cash / Debt
-88.7-95.47-88.68-57.65-11.0113.4-28.13-29.44
Net Cash Per Share
-1.45-1.96-2.33-1.71-0.430.65-0.23-0.25
Working Capital
22.660.3625.323.5249.7641.2512.8112.53
Book Value Per Share
-1.74-2.43-2.16-1.44-0.240.49-0.57-0.48
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).